Co-administered oral drugs in the gastrointestinal lumen

Co-administered oral drugs in the gastrointestinal lumen refers to the site and process of physicochemical drug-drug interactions (DDIs) that occur before systemic absorption. These interactions typically involve one drug altering the absorption of another through mechanisms such as chelation, where metal ions like calcium or iron bind to drugs like tetracyclines or fluoroquinolones, forming non-absorbable complexes (StatPearls, 2023). Additionally, drugs that alter gastric pH, such as proton pump inhibitors or antacids, can significantly affect the solubility and dissolution of pH-sensitive medications (FDA, 2020). Other mechanisms include adsorption by agents like cholestyramine or activated charcoal, which can sequester drugs in the gut lumen and prevent their entry into the bloodstream (Journal of Pharmaceutical Sciences, 2017). These luminal interactions are a major cause of variable drug response and can lead to treatment failure if not managed by appropriate dosing intervals. Understanding these processes is essential for clinical pharmacology and ensuring patient safety during polypharmacy. Managing these interactions often requires staggered dosing or alternative formulations to ensure optimal therapeutic outcomes.

Other names

Luminal drug-drug interactionsPhysicochemical drug interactionsGastrointestinal drug interactionsPre-absorptive drug interactions

Physicochemical interactions including chelation, adsorption, complexation, and pH-mediated changes in solubility or ionization within the gastrointestinal tract (StatPearls, 2023; Journal of Pharmaceutical Sciences, 2017).